B+
Bull case
25%
Probability
Target price
$9.00
+95.2% vs current
KLRS
Kalaris TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.00
-13.2% vs current
B-
Bear case
30%
Probability
Target price
$1.50
-67.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-26
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.6
Score
AI commentary
Primary-source support is solid, but the setup still looks like a cautious filing-and-clinical-monitoring story rather than a broad positive rerating. The deterministic prior shifted negative versus the earlier baseline, recent trusted-news evidence is sparse, analyst revision visibility is effectively unavailable, and the peer set is loose. That combination keeps confidence capped despite adequate cash runway and ongoing trial execution.
RankAlpha Sentiment Codex - 2026-06-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystHigher R&D spend reflects site expansion and enrollment progress [#SEC-8K-2026-05-12]High impact
First-quarter R&D expense rose to $7.6 million from $6.0 million, which management tied to CRO and other clinical expenses as additional sites were opened and patients enrolled. That is a constructive execution signal, but it also reinforces the ongoing burn profile.
2027-06-30eventTH103 Phase 1b/2 preliminary data remains the main rerating event [#SEC-8K-2026-05-12][#SEC-8K-2026-03-17]High impact
Company disclosures continue to frame preliminary Phase 1b/2 data for TH103 in 1H 2027 as the key value inflection, with the study intended to inform dose selection for potential Phase 3 development. For a low-coverage single-program biotech, this remains the dominant upside and downside catalyst.
2027-10-01catalystCash runway into Q4 2027 supports execution but does not remove financing risk [#SEC-8K-2026-05-12]High impact
Kalaris reported $104.9 million of cash, cash equivalents, and marketable securities as of March 31, 2026 and said that balance should fund operations into the fourth quarter of 2027. That reduces near-term dilution pressure, but the company is still funding clinical development ahead of a major data readout.
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-26 • Updated nightlySource: Internal modelMethodology